NCT02455297终止2 期
A Single-arm, Open-label Phase IIa Study to Evaluate the Efficacy and Safety of Copanlisib Monotherapy in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL), Who Failed Ibrutinib Treatment or Were Unable to Tolerate Ibrutinib
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Bayer
- 入组人数
- 4
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
The primary objective of this study is to assess objective response rate (ORR) in patients with relapsed or refractory MCL who failed ibrutinib treatment or were unable to tolerate ibrutinib.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed MCL
- •Patients who have previously received treatment with ibrutinib (modified by amendment 1), including:
- •Completion of at least 1 cycle of treatment with ibrutinib and confirmed evidence of disease progression or refractoriness to treatment or
- •Discontinuation of ibrutinib treatment at an earlier time due to toxicity
- •Measurable disease according to the Lugano Classification
- •At least 28 days or 5 half-lives, whichever is shorter, from the completion of anti-cancer treatment (including, but not limited to, immunotherapy, chemotherapy, targeted therapy and biologic therapy) to the start of study treatment, excluding ibrutinib where the window may be less and at minimum 3 days (modified by amendment 1)
- •Availability of fresh tumor tissue at screening
- •Male or female patients ≥ 18 years old
- •ECOG (Eastern Cooperative Oncology Group) performance status of ≤ 2
- •Left ventricular ejection fraction (LVEF) by echocardiogram or multiple gated acquisition (MUGA) scan ≥ the lower limit of normal (LLN) for the Institution
- •Adequate bone marrow, liver and renal function
排除标准
- •Any of the following as the only site(s) of disease: palpable lymph nodes not visible on imaging studies, skin lesions, or bone marrow involvement only
- •Current central nervous system (CNS) involvement by lymphoma
- •New York Heart Association (NYHA) class III or IV heart disease
- •Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months). Myocardial infarction less than 6 months before start of study treatment
- •Uncontrolled arterial hypertension despite optimal medical management (per investigator's assessment) (modified by amendment 1)
- •Type I or II diabetes mellitus with HbA1c > 8.5% at screening (modified by amendment 1)
- •Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before start of study treatment. However, if a patient has recovered to ECOG performance status of ≤ 2 he/she may be enrolled provided that other eligibility criteria are met
- •Ongoing or active infection of Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 3
- •Known history of human immunodeficiency virus (HIV) infection
- •Acute or chronic hepatitis B (HBV) or hepatitis C (HCV) infection requiring concomitant treatment prohibited by this protocol (i.e.immunosuppressive therapy)
- •History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator)
- •Prior treatment with PI3K inhibitor(s)
- •Cytomegalovirus (CMV) PCR positive at baseline
研究组 & 干预措施
Copanlisib
Experimental
Copanlisib (BAY80-6946) solution for IV infusion
干预措施: Copanlisib (BAY80-6946) (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: 24 weeks
ORR is defined as the proportion of patients who have a best overall response of complete response (CR) or partial response (PR) during study conduct according to the criteria defined by the Lugano response criteria in NHL 2014.
次要结局
- Complete response rate (CRR)(24 weeks)
- Disease control rate (DCR)(24 weeks)
- Progression-free survival (PFS)(24 weeks)
- Duration of response (DOR)(24 weeks)
- Overall survival (OS)(24 weeks)
- Number of participants with treatment emergent adverse events (TEAEs) as a measure of safety and tolerability(Approximately 7 months)
研究者
相似试验
已完成
2 期
A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET AmplificationNeoplasm MalignantNCT02435121Sanofi1
已完成
2 期
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or CholangiocarcinomaNeoplasmNCT02699606Janssen Research & Development, LLC35
终止
2 期
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)Thyroid Carcinoma, AnaplasticNCT02657369Eisai Inc.34
终止
2 期
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p DeletionB-cell Chronic Lymphocytic Leukemia (CLL) With 17p DeletionNCT02044822Gilead Sciences102
终止
2 期
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast CancerTriple Negative Breast CancerNCT02984683Sanofi23